【摩根大通:百济神州肿瘤业务上升,评级“增持”,目标价上调】摩根大通发表报告称,在与百济神州管理层交流和参与业绩电话会议后,更确定其肿瘤学业务快速上升。去年第四季业绩向好,收入年增约 35%,主因泽布替尼销售强劲及产品管线研发进度快。 该行预测,若 2025 年公司研发管线多个项目更新研究进展,可降临床风险及提升价值,推动股价上升,预计市场普遍预期将向上修正。摩通认为百济神州今年或录得美国通用会计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.